Karolinska Development's Modus Therapeutics Gets Approval For 2nd Part Of Phase 2 Study
RefinitivLess than 1 min read
Karolinska Development AB KDEV:
REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY MODUS THERAPEUTICS RECEIVES APPROVAL FOR SECOND PART OF PHASE 2 STUDY IN CHRONIC KIDNEY DISEASE WITH ANEMIA
Login or create a forever free account to read this news